Abstract
Background: Breast cancer in young women (<45 years) often exhibits aggressive biological behavior and poor prognosis. Among molecular markers, p53 and Ki-67 have been widely investigated for their roles in tumor progression and prognostic implications; Objectives: This study aimed to evaluate the relationship between p53 and Ki-67 expression and clinicopathologic characteristics in young breast cancer patients.
Materials and methods: A cross-sectional descriptive study was conducted on 51 patients under 45 years old diagnosed with invasive breast carcinoma at Hue University of Medicine and Pharmacy Hospital between January 2023 and June 2025. Hematoxylin–eosin and immunohistochemistry (p53, Ki-67, ER, PR, Her2) were performed. Associations between markers and clinicopathologic features were analyzed using the Chi-square test, with statistical significance set at p<0.05.
Results: The mean age was 38.5 years, with the 35–40 age group accounting for 56.9%. The predominant histologic type was invasive carcinoma of no special type (NST, 76.5%). Stage II–III tumors represented nearly 80% of cases, with axillary lymph node metastasis observed in 58.8%. p53 positivity was found in 41.2% of cases, while high Ki-67 expression (≥14%) was detected in 82.5%. p53 positivity tended to be higher in grade III tumors (62.5%) without statistical significance (p=0.057). High Ki-67 expression was significantly associated with histologic grade (p<0.05) but not with tumor size, nodal status, or stage. Importantly, a significant association was observed between p53 and Ki-67 expression: 90.5% of p53-positive tumors also showed high Ki-67 (p<0.05).
Conclusion: High expression of p53 and Ki-67 is common in breast cancer among young women, reflecting enhanced proliferative activity and higher malignancy. The combined evaluation of p53 and Ki-67 may help explain the poor prognosis in this population and support their potential utility in risk stratification and personalized treatment approaches.
| Published | 2026-06-28 | |
| Fulltext |
|
|
| Language |
|
|
| Issue | Vol. 16 No. 3 (2026) | |
| Section | Original Articles | |
| DOI | 10.34071/jmp.2026.3.731 | |
| Keywords | KBreast cancer, young women, p53, Ki-67, histopathology. Ung thư vú, phụ nữ trẻ, p53, Ki-67, giải phẫu bệnh. |
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright (c) 2026 Hue Journal of Medicine and Pharmacy
Sung H, Ferlay J, Siegel R, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians 2021; 71(3):209-249.
Anders CK, Johnson R, Litton J, Phillips M, Bleyer A. Breast cancer before age 40 years. Seminars in Oncology. 2009; 36(3):237-249.
Foo CS, Su D, Chong CK, Chng HC, Tay KH, Low SC, et al. Breast cancer in young Asian women: study on survival. ANZ Journal of Surgery. 2005; 75(7):566-572.
Assi HA, Khoury KE, Dbouk H, Khalil LE, Mouhieddine TH, El Saghir NS. Epidemiology and prognosis of breast cancer in young women. Journal of Thoracic Disease. 2013; 5(Suppl 1):S2-S8.
Nguyen SM, Nguyen QT, Nguyen LM, Pham AT, Luu HN, Tran HTT, et al. Delay in the diagnosis and treatment of breast cancer in Vietnam. Cancer Medicine. 2021; 10(21):7683-7691.
Trieu PD, Mello-Thoms C, Brennan PC. Female breast cancer in Vietnam: a comparison across Asian specific regions. Cancer Biology & Medicine. 2015; 12(3):238-245.
Silwal-Pandit L, Langerød A, Børresen-Dale AL. TP53 Mutations in Breast and Ovarian Cancer. Cold Spring Harb Perspect Med. 2017; 7(1):a026252.
Dobes P, Podhorec J, Coufal O, Jureckova A, Petrakova K, Vojtesek B, et al. Influence of mutation type on prognostic and predictive values of TP53 status in primary breast cancer patients. Oncol Rep. 2014; 32(4):1695-1702.
Hwang SH, Baek SH, Lee MJ, Kook Y, Bae SJ, Ahn SG, et al. Clinical Relevance of TP53 Mutation and Its Characteristics in Breast Cancer with Long-Term Follow-Up Date. Cancers (Basel). 2024; 16(23):3899.
Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. Journal of the National Cancer Institute. 2011; 103(22):1656-1664.
Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M, et al. Tailoring therapies-improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Annals of Oncology. 2015; 26(8):1533-1546.
Zhang G, Shi Z, Liu L, Yuan H, Pan Z, Li W, et al. The prognostic relevance of p53 and Ki-67 to chemotherapy sensitivity and prognosis in triple-negative breast cancer. Translational Cancer Research. 2021; 10(2):1082-1087.
Bocchi M, Sousa Pereira N, Furuya RK, Motoori Fernandes CY, Losi-Guembarovski R, Vitiello GAF, et al. Expression of Ki67 and p53 Proteins: Breast Cancer Aggressivity Markers in Brazilian Young Patients. Journal of Adolescent and Young Adult Oncology. 2021; 10(4):379-388.
Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020; 77(2):181-185.
Pham T, Bui L, Kim G, Hoang D, Tran T, Hoang M. Cancers in Vietnam-Burden and Control Efforts: A Narrative Scoping Review. Cancer Control. 2019; 26(1):1073274819863802.
Dang Cong T, Nguyen Thanh T, Nguyen Phan QA, Hoang Thi AP, Nguyen Tran BS, Nguyen Vu QH. Correlation between HER2 Expression and Clinicopathological Features of Breast Cancer: A Cross-Sectional Study in Vietnam. Asian Pacific Journal of Cancer Prevention: APJCP. 2020; 21(4):1135-1142.
Levine AJ. p53: 800 million years of evolution and 40 years of discovery. Nature Reviews Cancer. 2020; 20(8):471-480.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. The Lancet Oncology. 2010; 11(2):174-183.
Inwald EC, Klinkhammer-Schalke M, Hofstädter F, Zeman F, Koller M, Gerstenhauer M, et al. Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Research and Treatment. 2013; 139(2):539-552.
Nguyen Phuong Thao T, Nguyen Dinh Tuan D, Dang Cong T, Vo Thi Hanh T, Le Thi Thu T. Studying on correlation between Ki-67 index and histopathological and immunohistochemical characteristics in invasive breast carcinoma. Hue Journal of Medicine and Pharmacy. 2024 Jun; 14(3):172.